MINAPHARM Pharmaceuticals (EGX:MIPH)
Egypt · Delayed Price · Currency is EGP 331.12
0.00 (0.00%)
At close: Feb 2, 2026
MINAPHARM Pharmaceuticals Income Statement
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 6,924 | 5,665 | 3,892 | 3,621 | 3,005 | 2,361 | |
Revenue Growth (YoY) | 56.56% | 45.55% | 7.50% | 20.47% | 27.29% | 15.11% |
Cost of Revenue | 4,297 | 3,728 | 2,640 | 2,124 | 1,820 | 1,457 |
Gross Profit | 2,628 | 1,937 | 1,252 | 1,496 | 1,185 | 904.48 |
Selling, General & Admin | 1,072 | 828.91 | 718.51 | 474.95 | 392.79 | 326.6 |
Research & Development | 191.87 | 131.26 | 151.27 | 59.35 | 45.84 | 39.08 |
Operating Expenses | 1,305 | 1,003 | 876.91 | 531.63 | 431.37 | 365.68 |
Operating Income | 1,323 | 933.85 | 374.66 | 964.74 | 753.96 | 538.8 |
Interest Expense | -747.42 | -593.68 | -254.46 | -62.17 | -48.84 | -69.3 |
Interest & Investment Income | 60.38 | 46.56 | 14.06 | 9.55 | 5.08 | 5.8 |
Currency Exchange Gain (Loss) | -101.64 | 10.67 | -37.3 | 37.52 | -1.76 | 1.64 |
Other Non Operating Income (Expenses) | -213.42 | -117.27 | -63.76 | -69.3 | -40.66 | -45 |
EBT Excluding Unusual Items | 320.83 | 280.12 | 33.2 | 880.34 | 667.79 | 431.95 |
Gain (Loss) on Sale of Assets | -0.14 | -0.45 | -0.17 | - | 0.46 | - |
Pretax Income | 320.7 | 279.67 | 33.03 | 880.34 | 668.25 | 431.95 |
Income Tax Expense | 170.94 | 118.57 | 10.67 | 249.44 | 193.38 | 121.27 |
Earnings From Continuing Operations | 149.75 | 161.11 | 22.36 | 630.89 | 474.87 | 310.68 |
Minority Interest in Earnings | -8.85 | -4.04 | -54.35 | -18.23 | -8.46 | -9.9 |
Net Income | 140.9 | 157.07 | -31.99 | 612.66 | 466.41 | 300.78 |
Preferred Dividends & Other Adjustments | 28.91 | 28.91 | 23.4 | 22.75 | 18.7 | 15.53 |
Net Income to Common | 111.99 | 128.15 | -55.39 | 589.91 | 447.71 | 285.25 |
Net Income Growth | - | - | - | 31.36% | 55.06% | 113.18% |
Shares Outstanding (Basic) | 11 | 11 | 11 | 11 | 12 | 12 |
Shares Outstanding (Diluted) | 11 | 11 | 11 | 11 | 12 | 12 |
Shares Change (YoY) | - | - | -3.57% | -6.67% | - | - |
EPS (Basic) | 10.12 | 11.58 | -5.01 | 51.41 | 36.42 | 23.20 |
EPS (Diluted) | 10.12 | 11.58 | -5.01 | 51.41 | 36.42 | 23.20 |
EPS Growth | - | - | - | 41.17% | 56.95% | 102.17% |
Free Cash Flow | -436.5 | -697.45 | -1,292 | -598.45 | -180.6 | 286.84 |
Free Cash Flow Per Share | -39.45 | -63.04 | -116.81 | -52.16 | -14.69 | 23.33 |
Dividend Per Share | 2.500 | 2.500 | 1.650 | 2.800 | 2.922 | 2.700 |
Dividend Growth | 51.52% | 51.52% | -41.07% | -4.17% | 8.21% | - |
Gross Margin | 37.95% | 34.19% | 32.16% | 41.33% | 39.44% | 38.31% |
Operating Margin | 19.11% | 16.48% | 9.63% | 26.65% | 25.09% | 22.82% |
Profit Margin | 1.62% | 2.26% | -1.42% | 16.29% | 14.90% | 12.08% |
Free Cash Flow Margin | -6.30% | -12.31% | -33.21% | -16.53% | -6.01% | 12.15% |
EBITDA | 1,624 | 1,172 | 536.04 | 1,086 | 835.91 | 621.7 |
EBITDA Margin | 23.45% | 20.69% | 13.77% | 29.99% | 27.81% | 26.33% |
D&A For EBITDA | 300.98 | 238.38 | 161.38 | 121.14 | 81.95 | 82.9 |
EBIT | 1,323 | 933.85 | 374.66 | 964.74 | 753.96 | 538.8 |
EBIT Margin | 19.11% | 16.48% | 9.63% | 26.65% | 25.09% | 22.82% |
Effective Tax Rate | 53.30% | 42.39% | 32.29% | 28.34% | 28.94% | 28.07% |
Advertising Expenses | - | - | - | 8.4 | 15.38 | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.